United States Patent 5,708,011: Claim Scope, Validity, Expiration, and Levobupivacaine Patent Landscape

U.S. Patent No. 5,708,011 covers a method of treating pain with levobupivacaine in human patients who have, or are predisposed to, depressed myocardial contractility. The patent does not broadly claim levobupivacaine, bupivacaine, a formulation, or a manufacturing process. Its protection is limited to a patient-selection and treatment method requiring administration of levobupivacaine substantially free of dexbupivacaine.

The patent was issued on January 13, 1998, to Chiroscience Limited. Based on its 1993 priority date and the standard 20-year patent term applicable to the underlying application, the patent expired in approximately 2014. It therefore does not create current U.S. patent exclusivity for levobupivacaine or for the claimed treatment method.[1]

What does U.S. Patent 5,708,011 protect?

The patent protects the use of substantially enantiopure levobupivacaine for anesthetic treatment of pain in patients with elevated cardiovascular vulnerability.

The independent claim requires each of the following elements:

Claim element	Scope
Treatment type	Anesthetic treatment of pain
Patient	Human patient
Patient condition	Has, or is predisposed to having, depressed myocardial contractility
Active ingredient	Levobupivacaine or a salt thereof
Stereochemical limitation	Levobupivacaine is substantially free of dexbupivacaine
Dosage limitation	Administration of an effective amount

The claim is a method-of-use claim. It does not cover every administration of levobupivacaine. A product or treatment falling outside the patient population, therapeutic purpose, or stereochemical limitation would not literally meet claim 1.

The patent’s technical premise is that levobupivacaine, the S-enantiomer of bupivacaine, has a lower risk of cardiovascular toxicity than racemic bupivacaine or dexbupivacaine. The claimed population was selected because impaired myocardial contractility or cardiovascular comorbidity could increase the clinical significance of local-anesthetic cardiotoxicity.

How should the phrase “substantially free of dexbupivacaine” be construed?

“Substantially free of dexbupivacaine” is a material claim limitation, but claim 1 does not specify a numerical purity threshold. Claim 7 provides a more concrete dependent limitation by requiring at least 90% enantiomeric excess with respect to dexbupivacaine.

Enantiomeric excess is calculated as:

[ ee = \frac{[S]-[R]}{[S]+[R]} \times 100 ]

For levobupivacaine, the S-enantiomer is the desired active enantiomer and dexbupivacaine is the R-enantiomer. At least 90% enantiomeric excess corresponds to approximately 95% S-enantiomer and 5% R-enantiomer.

The relationship between claims 1 and 7 is important:

Claim 1 requires a product substantially free of dexbupivacaine but gives no express percentage.
Claim 7 expressly requires at least 90% enantiomeric excess.
A product satisfying claim 7 necessarily falls within claim 1.
A product could potentially fall within claim 1 while having less than 90% enantiomeric excess, depending on how “substantially free” is construed from the specification and prosecution history.
A racemic bupivacaine product would not ordinarily satisfy the limitation.

A court would likely examine the patent specification, prosecution history, analytical methods, and technical meaning of “substantially free” at the relevant filing date. The absence of a numerical threshold in claim 1 creates greater claim-construction uncertainty than claim 7, but that uncertainty has no current commercial consequence because the patent has expired.

What conditions and patient groups are covered by dependent claims 2 through 9?

The dependent claims define narrower patient populations and concomitant-treatment scenarios.

Claim	Added limitation
2	Hypertension, renal disease, post-myocardial infarction, ischemia, diabetes, viral infection, or alcohol dependence
3	Prior cardiac surgery, multiple organ failure, valve replacement, or pacemaker
4	Concomitant therapy with a cardio-depressant drug
5	Concomitant antihypertensive therapy using a calcium-channel blocker
6	Concomitant cytotoxic-drug therapy
7	At least 90% enantiomeric excess relative to dexbupivacaine
8	Calcium-channel blocker is verapamil
9	Heart failure at NYHA class II, III, or IV

Claims 2 and 3 are alternative-list claims. A patient need satisfy only one listed condition to meet the additional limitation. Claim 8 depends on claim 5 and therefore requires both the calcium-channel-blocker limitation and verapamil.

Claim 9 is narrower than claim 1 because it identifies a recognized heart-failure classification. NYHA class II, III, or IV generally corresponds to increasing functional limitation, but the claim language does not expressly require a particular ejection fraction, hospitalization history, or diagnostic test.

Does the patent cover levobupivacaine products or formulations?

No. U.S. Patent 5,708,011 does not claim a levobupivacaine composition as such.

It does not expressly claim:

Levobupivacaine hydrochloride as a chemical compound;
A sterile injectable solution;
A particular concentration;
A vial, ampoule, syringe, or infusion bag;
A preservative-free formulation;
A pH range;
A delivery device;
A sustained-release formulation;
A manufacturing or purification process; or
A method for separating levobupivacaine from dexbupivacaine.

The patent can be infringed through use of a qualifying product, even if the product itself is not claimed. A formulation patent or process patent would be legally distinct and would need to be analyzed separately.

The patent’s formulation relevance arises from the purity requirement. A manufacturer using a levobupivacaine material that contains dexbupivacaine would need to assess whether the product remains “substantially free” of the R-enantiomer. That issue concerns claim scope and evidence, not a separate composition claim.

What is the patent expiration date for U.S. Patent 5,708,011?

The patent expired in approximately 2014.

Event	Date or period
Earliest priority	1993
U.S. application filing	1995
Patent grant	January 13, 1998
Expected ordinary expiration	Approximately 2014
Current enforceability	Expired
Current blocking effect	None

The expiration analysis is based on the patent’s 1993 priority chain and the 20-year term framework applicable to the relevant U.S. application. Any patent-term adjustment or extension would need to appear in the USPTO patent record. Patent expiration eliminates the right to enforce the claims against later users, manufacturers, suppliers, or sponsors.

Expiration does not invalidate historical infringement claims that accrued while the patent was in force, subject to applicable limitation periods and other defenses. It does eliminate prospective enforcement.

Was U.S. Patent 5,708,011 eligible for a Hatch-Waxman patent-term extension?

The patent’s subject matter was a method of using levobupivacaine, while regulatory approval concerned the drug product. A patent-term extension under 35 U.S.C. § 156 is limited by statutory eligibility requirements, including whether the patent claims the approved product, a method of using the approved product, or a manufacturing process for the approved product.

No current patent-term extension or supplementary period appears to preserve enforceability of U.S. Patent 5,708,011. The patent should therefore be treated as expired for U.S. commercial planning.

What was the FDA and Orange Book significance of the patent?

Levobupivacaine was developed as a single-enantiomer local anesthetic and marketed under the Chirocaine name in jurisdictions where approved. The relevant FDA regulatory record must be evaluated at the product and NDA level, not solely by patent number.

The patent is not a current Orange Book barrier because it has expired. Even if the patent was previously listed for an approved product or method of use, an expired listing cannot prevent an ANDA applicant from obtaining approval or launching a product after all other regulatory requirements are satisfied.

The main regulatory distinctions are:

A product-specific NDA establishes approval of the drug product.
An ANDA applicant may challenge listed patents through a Paragraph IV certification.
A method-of-use patent can be relevant only if it is properly listed and tied to an approved indication.
A patent that has expired does not support a continuing Paragraph IV litigation stay.
FDA approval and patent freedom to operate are separate questions.

For levobupivacaine, commercial risk is more likely to arise from regulatory approval, supply, formulation development, product liability, and market demand than from U.S. enforcement of Patent 5,708,011.

What would a Paragraph IV challenge to this patent have involved?

A Paragraph IV certification would have alleged that the patent was invalid, unenforceable, or not infringed. The principal arguments against this patent would likely have been:

Anticipation

A challenger would search for prior disclosure of:

Levobupivacaine administration for pain;
Use of the S-enantiomer in anesthesia;
Reduced cardiovascular toxicity compared with racemic bupivacaine;
Treatment of patients with cardiac disease or depressed contractility; and
Enantiomeric purity levels meeting the claims.

Anticipation would require one prior-art reference to disclose all elements of the asserted claim in an enabling manner.

Obviousness

Obviousness would likely be the central validity issue. A challenger could argue that:

Levobupivacaine was known as an enantiomer of bupivacaine;
Its use as a local anesthetic was known or predictable;
Cardiovascular-risk patients were an expected target population for a less cardiotoxic enantiomer; and
The claim merely selected a known drug for a foreseeable clinical subgroup.

The patent holder would counter that the claimed patient-selection strategy produced an unexpected safety advantage, particularly in patients with reduced cardiac reserve, and that the prior art did not provide a reasonable expectation of success for the claimed use.

Claim construction

A challenger could contest:

The meaning of “depressed myocardial contractility”;
The meaning of “disposed to having”;
The scope of “substantially free” of dexbupivacaine;
The meaning of “effective amount”; and
Whether “anesthetic treatment of pain” requires a particular anesthetic technique.

Claim 7 is more objective than claim 1 because it includes a measurable enantiomeric-excess threshold.

Enablement and written description

A challenge could address whether the patent adequately supports the broad population defined by claim 1, including all patients predisposed to depressed myocardial contractility and all effective administration regimens. The patent holder would rely on examples, pharmacology data, and the common technical knowledge concerning local-anesthetic use.

Because the patent is expired, these historical validity questions no longer create a forward-looking launch barrier.

What generic-entry risks exist for levobupivacaine?

Current generic-entry risk from Patent 5,708,011 is zero as a matter of prospective patent enforcement because the patent has expired.

Potential commercial entry issues remain separate:

Risk area	Current significance
Expired method patent	No continuing exclusivity
Unexpired formulation patent	Must be checked separately
Unexpired manufacturing patent	Must be checked separately
FDA approval pathway	Product-specific
Orange Book listings	Must be reviewed for the current reference product
Enantiomeric purity	Quality and regulatory issue
Supply of pharmaceutical ingredient	Possible commercial constraint
Clinical adoption	Market-demand issue
Patent litigation	No continuing action based solely on this expired patent

A generic sponsor could still face regulatory or commercial obstacles unrelated to this patent. Those may include formulation equivalence, analytical-method validation, labeling, manufacturing controls, and the availability of an approved reference product.

How strong was the patent estate around levobupivacaine?

U.S. Patent 5,708,011 was a targeted use patent rather than a comprehensive product estate.

Strengths

It focused on a clinically important risk population.
It linked stereochemical purity to cardiovascular safety.
Claim 1 covered a broad category of patients with depressed myocardial contractility.
Dependent claims captured identifiable high-risk conditions and concomitant therapies.
The claim structure could support infringement theories based on labeled or documented use.

Weaknesses

It did not claim levobupivacaine as a molecule.
It did not claim a formulation or manufacturing process.
“Substantially free” lacked a numerical threshold in the independent claim.
“Disposed to having depressed myocardial contractility” is potentially broad and fact-intensive.
The medical-use concept could face obviousness arguments based on known single-enantiomer pharmacology.
The patent expired approximately a decade ago.

The patent was therefore commercially useful during the protected period but does not constitute a durable product-level barrier today.

What licensing and commercialization arrangements affected levobupivacaine?

Chiroscience was the originating company associated with levobupivacaine and the patent. Commercial development and distribution involved licensing and collaboration arrangements concerning Chirocaine. Public company disclosures from the period identify commercial partnerships involving Abbott Laboratories and related commercialization rights.

Those arrangements could have affected who controlled regulatory filings, manufacturing, marketing, and enforcement. They do not extend the statutory patent term. Any assessment of historical damages or contract rights would require the specific license agreement and the applicable jurisdiction.

What patent litigation affects U.S. Patent 5,708,011?

The patent’s expiration means that no current injunction or launch-blocking order can be based on its claims. A historical lawsuit, settlement, or covenant not to sue could still matter for past conduct, but it would not restore exclusivity after expiration.

No present commercial conclusion should be drawn from the existence of the issued patent alone. The relevant current questions are whether separate levobupivacaine patents remain unexpired, whether any current Orange Book listing is active, and whether a product-specific regulatory exclusivity period remains.

How does Patent 5,708,011 compare with product and formulation patents?

Patent type	What it protects	Relevance to levobupivacaine
Compound patent	The active chemical entity	Usually strongest, but likely unavailable for an old known enantiomer
Enantiomer-separation patent	Production of the S-enantiomer	Can affect API manufacturing
Composition patent	Drug formulation or dosage form	Can delay follow-on formulations
Method-of-use patent	Use in a defined disease or patient group	Category covering Patent 5,708,011
Manufacturing-process patent	Synthesis, purification, crystallization	May create supplier-specific barriers
Device patent	Delivery system	Relevant to specialized administration
Regulatory exclusivity	FDA approval protection	Separate from patent term

Patent 5,708,011 is narrower than a compound or formulation patent but broader than a claim limited to one dosage regimen or one anesthetic procedure.

Key Takeaways

U.S. Patent 5,708,011 claims treatment of pain with levobupivacaine in patients with, or predisposed to, depressed myocardial contractility.
The claims require levobupivacaine substantially free of dexbupivacaine.
Claim 7 specifies at least 90% enantiomeric excess.
Dependent claims cover cardiovascular disease, renal disease, diabetes, post-cardiac-surgery patients, pacemaker patients, heart failure, cardio-depressant drugs, cytotoxic therapy, calcium-channel blockers, and verapamil.
The patent does not claim levobupivacaine as a compound, formulation, manufacturing process, or delivery device.
The patent expired approximately in 2014 and does not create current U.S. launch exclusivity.
Any present freedom-to-operate analysis must focus on separate formulation, process, device, regulatory, and Orange Book rights.
Historical validity issues would have centered on obviousness, the meaning of “substantially free,” and the breadth of the depressed-myocardial-contractility patient population.

FAQs

Does U.S. Patent 5,708,011 cover racemic bupivacaine?

No. The claims require levobupivacaine that is substantially free of dexbupivacaine. Racemic bupivacaine contains approximately equal amounts of both enantiomers and would not ordinarily meet that limitation.

Does the patent cover levobupivacaine used in dental anesthesia?

Only if every claim element is satisfied, including treatment of pain in a human patient with depressed myocardial contractility or a qualifying predisposition. Routine dental use in an otherwise healthy patient would generally fall outside the claimed population.

Does claim 9 require a formal heart-failure diagnosis?

Claim 9 requires heart failure at NYHA class II, III, or IV. Clinical records would likely need to support both the existence of heart failure and the applicable functional class.

Can an expired method-of-use patent block an ANDA launch?

No. An expired patent cannot support a continuing patent-based injunction or a statutory stay of FDA approval. Other unexpired patents or regulatory exclusivities could still affect the launch.

Is levobupivacaine still protected by the patent’s enantiomeric-purity requirement?

No. The purity limitation remains part of the historical claim text, but the patent’s expiration means that the limitation no longer creates enforceable U.S. exclusivity.

References

United States Patent and Trademark Office. (1998). U.S. Patent No. 5,708,011: Use of levobupivacaine in the treatment of pain.
United States Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent No. 5,708,011.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
Chiroscience Group plc. (1990s). Annual reports and regulatory disclosures concerning levobupivacaine and Chirocaine.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9321061	Oct 13, 1993
United Kingdom	9408014	Apr 22, 1994

PCT Information
PCT Filed	October 13, 1994	PCT Application Number:	PCT/GB94/02249
PCT Publication Date:	April 20, 1995	PCT Publication Number:	WO95/10277

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	150643	⤷ Start Trial
Austria	154758	⤷ Start Trial
Austria	210982	⤷ Start Trial
Austria	243036	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,708,011

Summary for Patent: 5,708,011